Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies
- PMID: 15713418
- DOI: 10.1016/j.bmcl.2004.12.068
Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies
Abstract
A screening assay program on HIV-protease was carried out on more than fifty commercially available N-protected amino acids and has revealed that those with a long side chain such as lysine, ornithine and arginine exhibited significant inhibition of HIV protease enzyme. The presence of an Fmoc group was found to be essential to obtain micromolar inhibitors and the addition of an alkyl group at the Nalpha-position resulted in the discovery of the lead compound 11 displaying a 5 nM inhibition constant. Although this new inhibitor series is not categorized among those mimicking the substrate with a non-hydrolyzable transition-state isoster, it was found very specific to inhibit HIV protease enzyme in comparison to the mammalian aspartyl proteases pepsin, renin and cathepsin. Furthermore, these inhibitors did not show any cytotoxicity at a concentration below 75 microM.
Similar articles
-
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.Bioorg Med Chem Lett. 2006 Jul 1;16(13):3459-62. doi: 10.1016/j.bmcl.2006.04.011. Epub 2006 Apr 27. Bioorg Med Chem Lett. 2006. PMID: 16644213
-
Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.Bioorg Med Chem Lett. 2004 Nov 15;14(22):5689-92. doi: 10.1016/j.bmcl.2004.08.039. Bioorg Med Chem Lett. 2004. PMID: 15482949
-
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.J Med Chem. 1996 Jun 7;39(12):2400-10. doi: 10.1021/jm950888f. J Med Chem. 1996. PMID: 8691434
-
Nonpeptidic potent HIV-1 protease inhibitors.Drug Des Discov. 1996 Apr;13(3-4):15-28. Drug Des Discov. 1996. PMID: 8874041 Review.
-
Design of potent aspartic protease inhibitors to treat various diseases.Arch Pharm (Weinheim). 2008 Sep;341(9):523-35. doi: 10.1002/ardp.200700267. Arch Pharm (Weinheim). 2008. PMID: 18763714 Review.
Cited by
-
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.Chem Rev. 2021 Mar 24;121(6):3238-3270. doi: 10.1021/acs.chemrev.0c00648. Epub 2021 Jan 7. Chem Rev. 2021. PMID: 33410674 Free PMC article. Review.
-
Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease.J Virol. 2005 Oct;79(19):12477-86. doi: 10.1128/JVI.79.19.12477-12486.2005. J Virol. 2005. PMID: 16160175 Free PMC article.
-
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.J Med Chem. 2016 Jun 9;59(11):5172-208. doi: 10.1021/acs.jmedchem.5b01697. Epub 2016 Jan 22. J Med Chem. 2016. PMID: 26799988 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information